Abu-Qurshin Ret al. Crohn's disease associated with pellagra and increased excretion of 5-hydroxyindolacetic acid. Am J Med Sci 313(2) (1997): 111-13.
Anderson H. Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43 (1994): 770-7.
Armstrong EP et al. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 10(3) (2004): 251-8.
Bays HE et al. Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE]). Am J Cardiol 91(6)(2003): 667-72.
Beers MH, Berkow R (eds). The Merck Manual of Diagnosis and Therapy, 17th edn. Whitehouse, NJ: Merck and Co. Inc., 2003.
Bolkent S et al. Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats. Biol Trace Elem Res 101(3) (2004): 219-29.
Canner BL et al. Mortality in Coronary Drug Project patients during a nine year post-treatment period. Am Coll Cardiol 8 (1986): 1245-55.
Capuzzi DM et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 91(11) (2003): 1304-10.
Chouinard G et al. Tryptophan, niacinamide, imipramine and their combination in depression. Acta Psychiatr Scand 59 (1979): 395-414.
Crouse JR 3rd. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 7(4) (1996): 321-6.
Elam MB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284(10) (2000): 1263-70.
Fonseca V. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Diabetes Care 26(1) (2003): 258.
Gale EA. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab 9.3 (1996): 375-9.
Ganji SH et al. Niacin and cholesterol; role in cardiovascular disease (Review). J Nutr Biochem 14(6) (2003): 298-305.
Gardner SF et al. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 16 (1996): 419-23.
Gardner SF et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 31(6) (1997): 677-82.
Gerber M et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 39(3) (2004): 419-25.
Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol 82(12A) (1998): 35-8U.
Goldberg AC. A meta-analysis of randomized controlled studies on the effects of Extended-Release niacin in women. Am J Cardiol 94(1) (2004): 121-4.
Greenbaum CJ et al. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 45(11) (1996): 1631-4.
Grundy SM et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial (Original Investigation). Arch Intern Med 162(14) (2002): 1568-9.
Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 5(6) (2004): 1385-98.
Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 82(12A) (1998): 82-4U.
Guyton JR et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol: Niaspan-Gemfibrozil Study Group. Arch Intern Med 160(8) (2000): 1177-84.
Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res 475(1-2) (2001): 45-56.
Hendler SS, Rorvik D (eds). PDRfor Nutritional Supplements. Montvale, NJ: Medical Economics Co., 2001.
Henkin Y et al. Rechallenge with crystalline niacin after drug induced hepatitis from sustained-release niacin. JAMA 264 (1990): 241-3.
Illingworth DR et al. Comparative effects of lovastatin and niacin in primary hypercholesterolaemia. Arch Intern Med 154 (1994): 1586-95.
Integrative Medicine Gateway (IMG). Unity Health 2001-06. Available at: www.imgateway.net (accessed 0306).
Ito MK. Niacin-based therapy for dyslipidemia: past evidence and future advances. Am J Manag Care 8 (12 Suppl) (2002): S315-22.
Ito MK. The metabolic syndrome; pathophysiology, clinical relevance, and use of niacin. Ann Pharmacother 38(2) (2004): 277-85.
Jacobs P, Wood L. Vitamin B3. Disease-a-Month 49(11) (2003): 658-63.
Jacobson TA et al. Fluvastatin with and without niacin for hypercholesterolaemia. Am J Cardiol 74 (1994): 149-54.
Jonas WB et al. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 45.7 (1996): 330-4.
Kaur K et al. An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia. Curr Ther Res 65(6) (2004): 455-69.
Kirkland J. Niacin and carcinogenesis. Nutr Cancer 46(2) (2003): 110-18.
Kobayashi M, Shimizu S. Nicotinic acid and nicotinamide. Nippon Rinsho 57(10) (1999): 2211-17.
Kwiterovich POJr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86 (12A) (2000): 5-10L.
Lampeter EF et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47.6 (1998): 980-4.
Levy DR, Pearson TA. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clin Cardiol 28(7) (2005): 317-20.
Lininger SW (ed). A-Z Guide to Drug-Herb-Vitamin Interactions. Healthnotes USA, 1999.
Llancapi P et al. Pellagra: diagnosis still valid. Rev Med Chil 126(4) (1998): 435-8 [in Spanish].
McCarty MF, Russell AL. Niacinamide therapy for osteoarthritis: does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes? Med Hypotheses 53.4 (1999): 350-60.
Mc Kenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164(7) (2004): 697-705.
Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69(6) (2003): 413-19.
Messamore E et al. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Vitamin B3 — Niacin
Schizophrenia Res 62(3) (2003): 251-8.
Meyers C et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 139(12) (2003): 996-1002. Meyers C et al. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15(6) (2004): 659-65. Mills E et al. The safety of over-the-counter niacin: A randomized placebo-controlled trial ISRCTN18054903.
BMC Clin Pharmacol 3(1) (2003): 4. Monteiro JP et al. Niacin metabolite excretion in alcoholic pellagra and AIDS patients with and without diarrhea. Nutrition 20(9) (2004): 778-82. Morgan JM et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91(12)
Morgan JM et al. The effects of niacin on lipoprotein subclass distribution. Prev Cardiol 7(4) (2004): 182-7. Morris MC et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol
Neurosurg Psychiatry 75(8) (2004): 1093-9. Murray MF et al. Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition 17(7-8) (2001): 654-6. Nabokina SM et al. Mechanism and regulation of human intestinal niacin uptake. Am J Physiol Cell Physiol 289(1) (2005): C97-103.
Packard C et al. Future Forum Editorial Board: High density lipoprotein: guardian of the vascular system? Int J
Clin Pract 56(10) (2002): 761-71. Pan J et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein (a) in diabetes.
Metabolism 51(9) (2002): 1120-7. ParraJL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7(2) (2003): 415-33. Perumal SS et al. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQIO: Effects on lipid peroxidation and antioxidants in mitochondria. Chemico-Biol Interact 152(1) (2005): 49-58. Pieper JA. Understanding niacin formulations. Am J Manag Care 8 (12 Suppl) (2002): S308-14. Pocoit F et al. Nicotinamide: Biological actions and therapeutic potential in diabetes prevention. Diabetologia 36 (1996): 574-6.
ProuskyJE. Pellagra maybe a rare secondary complication of anorexia nervosa: a systematic review of the literature. Altern Med Rev 8(2) (2003): 180-5. ProuskyJ, Seely D. The treatment of migraines and tension-type headaches with intravenous and oral niacin
(nicotinic acid): Systematic review of the literature. Nutr J 4 (2005): 3. Rakel D. Integrative Medicine. Philadelphia: Saunders, 2003; 592.
Rindone JP, Achacoso S. Effect of low-dose niacin on glucose control in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Ther 3(9) (1996): 637-9. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 94(3)
Rubic T et al. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette Al in monocytoid cells by niacin. Biochem Pharmacol 67(3) (2004): 411-19. Sadovsky R. Extended-release niacin for type 2 diabetes dyslipidemia. Am Fam Physician 66(10) (2002): 1982. Shara M et al. Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex. J Inorganic
Biochem 99(11) (2005): 2161-83. Smesny S et al. Potential use of the topical niacin skin test in early psychosis: a combined approach using optical reflection spectroscopy and a descriptive rating scale. J Psychiatric Res 37(3) (2003): 237-47. Smesny S et al. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.
Prostaglandins Leukot Essent Fatty Acids 72(6) (2005): 393-402. Tavares H et al. Increased phospholipase A2 activity in schizophrenia with absent response to niacin.
Schizophrenia Res 61(1) (2003): 1-6. Vitamin B3 — Niacin 1237
Taylor AJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23) (2004): 3512-7.
Veiling DA et al. Sustained-release niacin for prevention of migraine headache. Mayo Clin Proc 78(6) (2003): 770-1.
Virtanen SM, Aro A. Dietary factors in the aetiology of diabetes. Ann Med 26(6) (1994): 469-78.
Visaiii N et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev 15(3) (1999): 181-5.
Wahlqvist ML (ed.). Food and Nutrition, 2nd edn. Sydney: Allen & Unwin, 2002.
Wassef GN. Lipoprotein (a) in android obesity and NIDDM: a new member in 'the metabolic syndrome'. Biomed Pharmacother 53(10) (1999): 462-5.
Weitberg AB, Corvese D. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors. Biochem BiophysRes Commun 167(2) (1990): 514-19.
White Robinson A et al. The antilipidemic effects of plain and extended-release niacin. Prev Cardiol 3(3) (2000): 131-5.
Wilson JD et al. Harrison's Principles of Internal Medicine, 12th edn. New York: McGraw-Hill, 1991.
Wink J et al. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J 143(3) (2002): 514-18.
Yanardag R et al. Effects of a combination of niacin and chromium(III)-chloride on the skin and lungs of hyperlipemic rats. Biol Trace Elem Res 103(3) (2005): 249-60.
Yeganeh B et al. Combination of dietary phytosterols plus niacin or fenofibrate; effects on lipid profile and atherosclerosis in apo E-KO mice. J Nutr Biochem 16(4) (2005): 222-8.
Yim B, Chong P. Niacin-ERand lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Ann Pharmacother 37(1) (2003): 106-15.
Zhao XQ et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93(3) (2004): 307-12.
Was this article helpful?
If you weaken the center of any freestanding structure it becomes unstable. Eventually, everyday wear-and-tear takes its toll, causing the structure to buckle under pressure. This is exactly what happens when the core muscles are weak – it compromises your body’s ability to support the frame properly. In recent years, there has been a lot of buzz about the importance of a strong core – and there is a valid reason for this. The core is where all of the powerful movements in the body originate – so it can essentially be thought of as your “center of power.”